Feasibility and Efficacy of HABIT for Enhancing Daily Hand-Use Post Stroke
Launched by TEL AVIV UNIVERSITY · Jun 6, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of therapy called HABIT, which aims to help people who have had a stroke use their affected hand more in their daily lives. The therapy focuses on improving hand function for those who have mild difficulty using their hand after a stroke. Researchers are looking to see if this therapy is effective and practical for individuals who meet certain criteria.
To participate in the trial, you need to be an adult over 18 years old, speak Hebrew, and have experienced a stroke at least 6 months ago but no more than 10 years ago. You should also have some difficulty with your hand but still be able to walk and live independently. Participants will undergo assessments at the beginning of the study, before starting the HABIT therapy, and after completing the therapy to measure any improvements in hand use. The trial is currently recruiting participants, and it’s a great opportunity for those looking to enhance their hand function after a stroke.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18 and above residing in their own homes
- • Hebrew speakers
- • Up to 10 years post-stroke
- • Mild upper extremity motor impairment but still report difficulty using their hand. This will be determined by a total score of 43/66, including the Hand subtest score of 7/14 points of the Fugl-Meyer Motor Assessment.
- • No significant cognitive decline (score of 19 and above on Montreal Cognitive Assessment)
- • Able to walk with or without assistive devices
- • Able to provide informed consent by signing a consent form
- • Full function of both hands and independent in daily function prior to stroke
- Exclusion Criteria:
- • Other neurological conditions or psychiatrists
- • with moderate or significant proprioception deficit (Thumb Localization Test \>1)
About Tel Aviv University
Tel Aviv University (TAU) is a leading research institution in Israel, renowned for its commitment to advancing knowledge and innovation across various fields, including medicine and biomedical research. With a strong emphasis on interdisciplinary collaboration, TAU conducts cutting-edge clinical trials aimed at improving healthcare outcomes and developing novel therapeutic strategies. The university's robust network of researchers, state-of-the-art facilities, and partnerships with healthcare organizations enable it to contribute significantly to the global medical research community, fostering advancements that address critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tel Aviv, , Israel
Patients applied
Trial Officials
Debbie Rand
Principal Investigator
Tel Aviv University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported